1. Identification of NSC 47147 as a FADD-kinase inhibitor.
Identification of NSC as a FADD-kinase inhibitor. A, A549-FKR cells were treated with NSC and SP for 6 hours and CKI-7 for 1 hour at the indicated concentrations followed by bioluminescent measurement. NSC blocks phosphorylation of FADD with greater potency than the FADD-kinase inhibitors SP and CKI-7. B, A549-FKR cells were treated as described for FKR assay and lysates were analyzed with specific antibodies by Western blotting. Treatment with the FADD-kinase inhibitors CKI-7 and SP shows dose-dependent decrease in p-FADD protein that correlates with FKR activity. Total and p-β-catenin and p-c-jun, respective targets of CKI-7 and SP600125, have been shown for comparison. C, A549 and Jurkat cells were treated for 6 hours with NSC Western blot analysis reveals that NSC leads to a decrease in p-FADD and p-β-catenin levels.
Katrina A. Schinske et al. Mol Cancer Ther 2011;10:
©2011 by American Association for Cancer Research